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Abstract
Objective: This paper seeks to explain local variations in the use of anti-
biotics in the community and to assess the welfare loss due to heterogeneous
attitudes towards the risk of bacterial resistance.
Method: Quarterly data on antibiotic sales from 240 small areas in Switzer-
land over the course of one year are used. An econometric ad-hoc model with
spatial lags is proposed in which the demand for antibiotics varies according to
the socioeconomic characteristics of the population, the incidence of infections,
antibiotic price and local health care supply. Using residual variations we then
evaluate the welfare loss due to varying antibiotic prescription styles.
Results: Significant diﬀerences are observed in the per capita antibiotic
consumption across local areas. Individual income, the demographic structure
of the population, physician density and the price of drugs are all relevant
determinants. We estimate that unexplained variations may account for 12%
of the total antibiotic spending in the community, thus leading to a €6.8 ml
loss per year.
Conclusions: The understanding of determinants of variations in out-
patient antibiotic consumption may help to design more eﬀective policies to
counter the threat of bacterial resistance. Our estimate of the welfare loss
due to heterogeneous attitudes towards antibiotic treatment is comparable to
the expected cost of implementing measures to improve the dissemination of
information on bacterial resistance among patients and doctors.
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1 Introduction
The use of antibiotics is far from homogeneous across geographic areas. A European
cross-country comparison shows, for example, that the per capita outpatient antibi-
otic consumption in the Netherlands is three times lower than in France (Goossens
et al., 2005). Significant disparities are also observed across regions within a single
country. In Germany, the rate of outpatient antibiotic use per inhabitant is ap-
proximately two times greater in high consumption regions than in low consumption
regions (Kern et al., 2006).
This raises the question of optimal drug use, which is particularly important in the
case of antibiotics. Studies show that the increasing use of antibiotics is associated
with growing rates of bacterial resistance, which in turn reduce the eﬀectiveness of
antibiotic treatment (Boccia at al., 2004; Coast et al., 1998; McGowan, 2001; Levy,
1998).
The investigation of what lies behind such variation in antibiotic use across ge-
ographic regions may help to identify sources of ineﬃciency in consumption. Few
studies explore socioeconomic determinants of antibiotic use in the community.
Matuz et al. (2006) test associations between regional consumption of antibiotics
in Hungary and possible determinants using the Spearman correlation coeﬃcient
approach. Determinants include the population structure, the prevalence of diseases,
the per capita income, free access to medicines and the density of general practitioners
and pharmacies. A significant positive correlation exists between antibiotic use and
free access to selected medicines from the public health system, and between antibiotic
use and social assistance.
Filippini et al. (2006) use an econometric approach and posit an ad-hoc model for
the demand of outpatient antibiotics in Switzerland. They find evidence that antibi-
otic price, as well as other socioeconomic factors — such as the proportion of foreign
residents, the density of medical practices, cultural and educational diﬀerences, and
the per capita income — have a significant impact on antibiotic consumption.
While the above studies diﬀer in terms of statistical approach, the country under
investigation and determinants considered, both conclude that further analysis should
be undertaken to study the determinants of antibiotic consumption.
Although the literature is rich in studies exploring the variability of antibiotic con-
sumption at the hospital level 1, very few studies investigate diﬀerences in community
consumption across small areas. The focus on small geographic areas rather than on
regions (counties or cantons) is desirable because smaller areas possess greater homo-
geneity in terms of health conditions and other population characteristics (Parchman,
1995). Nilson and Laurell (2005) and Henricson et al. (1998) focus on antibiotic con-
sumption across city districts in Sweden and show that antibiotic use significantly
varies across groups of individuals. Using a cross-sectional population survey, Mus-
cat et al. (2006) examine epidemiological characteristics of antibiotic use in the
1Studies include evidence from Norway (Blix et al., 2005), Germany (De With et al., 2006),
Netherlands (Liem et al., 2005), Denmark (Müller-Pebody et al., 2004), France (Rogues et al.,
2004) and Switzerland (Bugnon-Reber et al., 2004).
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community in Denmark. Generally, these studies focus on specific determinants with
a descriptive approach rather than on identifying and estimating ad-hoc models of
antibiotic demand.2
The first purpose of this paper is to explore socioeconomic determinants of small
area variations in outpatient antibiotic use in Switzerland by means of a multivariate
parametric approach. We specify and estimate an ad-hoc model for the local demand
for antibiotics in outpatient care, which depends on antibiotic price, population in-
come, age structure, health status and some cultural aspects of the population, as
well as characteristics of the local antibiotic supply.
The second purpose of the paper is to assess the economic impact of physicians’
and patients’ heterogeneous attitudes towards the use of antibiotics, i.e. hetero-
geneity in the risk perception of bacterial resistance. A common denominator in
the analysis of small area variations is that significant diﬀerences in the utilisation
of health services remain unexplained after controlling for standard determinants of
demand and access. Many authors argue that heterogeneity in physicians’ practice
styles may be an important cause of diﬀerences in medical utilisation across small
areas (Wennberg, 1984; McPherson, 1990; Westert and Groenewegen, 1999; Grytten
and Sorrensen, 2003). In the use of antibiotics, after controlling for other factors,
a substantial degree of the remaining heterogeneity can be associated with physi-
cians’ and patients’ attitudes towards the risk of bacterial resistance (Harbath et al.,
2002). Perceived levels of non-susceptible bacteria may aﬀect physicians’ prescrip-
tion strategies and patients’ decisions (Rudholm, 2002; Laxminarayan andWeitzman,
2002). Although average national levels of bacterial resistance are generally common
knowledge, individual awareness of implications may be lacking.
To assess the impact of unobserved heterogeneity in practice style, Folland and
Stano (1989) assume that this is an omitted variable complementary to all the ex-
planatory variables considered in their model. Consequently, the unexplained vari-
ance can be interpreted as a measure of the impact of practice style on the con-
sumption of medical services. We argue, however, that unexplained variations from a
correctly specified ad-hoc model of the demand for antibiotics can be interpreted as
a measure of the impact of heterogeneous practices due to uncertainty of the magni-
tude of bacterial resistance and diﬀerent levels of risk perception. Parente and Phelps
(1990) propose a methodology to assess the welfare loss due to unexplained variations
in medical practice based on linear demand curves. We build on a similar approach
to calculate the welfare loss due to heterogenous practices in the use of antibiotics in
outpatient care.
The paper is organized as follows. Section 2 summarises the Swiss policy con-
text and describes variations in outpatient antibiotic use across 240 small areas. In
Section 3 we sketch a simple ad-hoc model for the local demand of antibiotics in
the community. A theoretical frame for the assessment of welfare loss due to unex-
2Econometric models have been used, for instance, to investigate small area variations in the per
capita utilisation rates of medical procedures (Folland and Stano, 1989), birthweight rates (Crosse
et al., 1997), rates of ventilation tube surgery (Asche and Coyte, 2005), and hospitalisation rates
for low back problems (Joines et al.,2003).
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plained variations is presented in Section 3.1. Results from econometric estimations
are discussed in Section 4, with Section 4.1 providing a calculation of the welfare
loss associated with unexplained variations. The paper’s conclusions are presented
in Section 5.
2 Small area variations
Switzerland is a federal state comprising 26 cantons. The country can be divided
into three macro-areas by grouping cantons linguistically (ie., German-, French- and
Italian-speaking cantons). Health care policy, and as a consequence, the organisation
of the health care system diﬀer from canton to canton. In general, however, the
health care system is based on a mixed (private-social) health insurance system.
Health insurance is mandatory for residents and the same basic contract is oﬀered
by competing private insurance companies. The insured can choose from a limited
menu of deductibles. Physicians are reimbursed using a straightforward fee-for-service
scheme. The remuneration system is not directly related to the prescription of drugs
but patients’ perceptions of doctors may be aﬀected by prescription strategies.
Although average individual antibiotic consumption in Switzerland is low com-
pared to other European countries, it varies greatly within the country. High levels
of antibiotic use may increase bacterial resistance. Moreover, there is the risk that
resistant bacteria may enter the food chain through livestock. The Swiss National
Science Foundation (2007) argues that resistance will very likely progress if no con-
tainment measures are undertaken. However, Switzerland is in a “pre-pandemic”
situation, where antibiotic resistance is not yet perceived as an important threat by
the population. Few major hospitals in the country prepare guidelines on antibiotic
use based on information on levels of bacterial resistance collected from cantonal lab-
oratory tests. Such information is generally released every one or two years and, in
some cases, is delivered to general practitioners. A national surveillance database on
bacterial resistance is being developed and currently provides information for some
macro regions.
As part of a larger project investigating outpatient consumption of antibiotics,
we collated data from the 240 contiguous market areas that make up Switzerland.
These market areas can be grouped to represent administrative units (the cantons)
and cultural/linguistic regions. Generally, a canton is made up of between 10 and
20 market areas. Each market area exhibits high level of internal homogeneity with
respect to population and health care provider density. The population varies between
4,980 and 125,275 inhabitants per area.3 Each area has at least 4 pharmacies and/or
drugstores. Local wholesale quarterly data on outpatient antibiotics at the product
level were obtained from IHA-IMS Health Market Research for the year 2002. Using
3This is smaller than the population generally observed in similar studies, for instance in Folland
and Stano (1989) who identify 15 areas in the State of Michigan to investigate intermarket varia-
tions in the per capita utilisation rate of surgical procedures. More recently, Dubois et al. (2002)
considered areas with population ranging between 16,052 and 166,316 individuals.
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Figure 1: Within-canton variations in per capita antibiotic use (2002).
the number of inhabitants4 and WHO standard doses we calculated the defined daily
doses sold to 1000 inhabitants per day (DID) for each of the areas.
This measure represents a good indicator of local outpatient antibiotic use. We
assume that antibiotic purchases by individuals outside their area of residence oﬀ-
set purchases by non-residents inside each area. We do not take into account the
diﬀerence, if any, between the quantity of antibiotics sold and the quantity actually
consumed, assuming patient non-compliance to be a negligible factor. Finally, the
potential mismatch between wholesale records and prescribing data due to seasonal
fluctuations of retailers’ stocks is assumed to have only a limited temporary eﬀect
and is likewise ignored.
As illustrated in Figure 1, there is a great heterogeneity in antibiotic use even
across small areas within cantons5. The mean DID (across the small areas) is 11.71
and varies between a minimum of 4.65 and a maximum of 16.77 at the cantonal level.
Note, however, that within-canton variation is much greater since the minimum DID
in a small area is 3.18 (AG), whereas the maximum DID value is 141.27 (ZH).
3 The model
There may be several reasons for variations in the use of antibiotics across small
areas. All other things being equal, we hypothesise that four main factors aﬀect inter-
4Information for the year 2002 were derived from projections using the population census of 2000.
5The box and whiskers plot illustrates antibiotic use within cantons. We aggregate 5 small
cantons into 2 bigger regions. Consequently, the number of cantons is reduced to 23. The horizontal
line inside the shaded box represents the mean cantonal consumption of antibiotics. The width
of the shaded box includes consumption in the second quartile, i.e. 50% of the small areas in the
canton. Finally, the length of the two whiskers illustrates the third quartile of observations, i.e. 75%
of the small areas.
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area variability: the incidence of community-acquired infections, the local supply
of community care, population characteristics (age structure and income, cultural
aspects) and the price of antibiotics. In addition, antibiotic use could be influenced
by the level of bacterial resistance and antibiotic consumption in adjacent areas. The
magnitude of bacterial resistance country-wide is known to doctors and patients, but
such figures are not broken down for smaller areas. We operate on the assumption
that bacterial resistance does not vary across local areas but that local doctors and
patients may have diﬀerent attitudes towards the use of antibiotics. This means that
the perceptions of the implications of bacterial resistance diﬀer across the areas.
We specify an ad-hoc demand model to explain variations in the per capita use of
outpatient antibiotics across the small areas. The dependant variable is the defined
daily doses per 1000 inhabitants described above. All other things being equal, we
assume that for the area i:
DIDi = f(Yi, POPji, INFki,DPHYi,DPHAi, Pi,DLATi, DBORi,DTt), (1)
where Yi is the average income of residents in the area i, POPji is the percentage
of the population in the j age range; INFki is a proxy for the health status of the
population represented by the incidence of k main bacterial infections at the cantonal
level; DPHYi and DPHAi are respectively the density of physicians and pharmacies
in the area; and Pi is the price of a defined daily dose in period t− 1. Lagged values
for prices are used to reduce the risk of endogeneity between quantities and prices.
DBORi is a dummy that captures any borderland eﬀects with neighboring coun-
tries and DLATi is a dummy that considers whether an area is mainly characterized
by Latin (French- and Italian-speaking) or German culture. Finally, DTt are time
dummies that identify the four quarters of the year, with DT4 (October, November,
December) the baseline quarter. Defined daily doses of outpatient antibiotics per
capita are expected to be higher during winter and lower in the spring and summer
periods, as pointed out by Goossens et al. (2005).
Since patients’ preferences for antibiotics in one area may reflect individuals’ atti-
tudes towards antibiotics in adjacent areas, we need to consider the potential impact
of spatial dependency. The issue is further discussed with the model specification at
the end of this section.
Our dataset includes quarterly information for the year 2002 and for the 240
regions on covariates defined in equation (1). Summary statistics are reported in
Table 1.
Among the idiosyncratic characteristics of the population we include the demo-
graphic structure, socioeconomic aspects and cultural attitudes. We consider five age
groups: 0-14, 15-25, 26-59, 60-74, and over 74. For example, if the antibiotic therapy
represents a time-saving choice for individuals in the work force, one might expect
that middle-aged individuals are more likely to use them, ceteris paribus. This hy-
pothesis is in accordance with the findings of Mousquès et al. (2003), who studied
general practitioners’ antibiotic prescriptions for rhynopharingitis infections. On the
other hand, the elderly may be less exposed to community-acquired infections, even
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Variable Description Mean Std dev.
DID Defined daily doses per 1000 inhabitants 11.714 13.061
Y Income per capita defined in CHF 23465 6849.4
POP1 Proportion of 0-14 in total population 0.1658 0.0243
POP2 Proportion of 15-25 in total population 0.1247 0.0173
POP3 Proportion of 26-59 in total population 0.4956 0.0314
POP4 Proportion of 60-74 in total population 0.1363 0.0213
POP5 Proportion of over 74 in total population 0.0776 0.0190
INF Incidence of common gastrointestinal infections 114.69 22.580
(salmonella and campylobacter) in 100000 inhabitants
INF2 Incidence of common respiratory infections 64.977 41.060
(streptococcus) in 100000 inhabitants
DPHY Density of physicians for 100000 inhabitants 565.21 1052.5
DPHA Density of pharmacies for 100000 inhabitants 35.098 39.112
P Price of a defined daily dose 3.7112 0.3113
DBOR Whether or not the area borders another country/ - -
other countries
DLAT Whether an area has a Latin (French and Italian) - -
or a German culture
Table 1: Variables notation and summary statistics.
though more susceptible, or be more concerned with the implications of bacterial re-
sistance and hence use less antibiotics. We hypothesise that children are more likely
to be prescribed an antibiotic than adults ceteris paribus. It can be argued that
doctors and patients may be concerned with the potential harmful eﬀect of delaying
antibiotic treatment for the very young.6 Resi et al. (2003) find that the percentage
of children receiving antibiotics decreases as they grow up. Whereas 70% of children
between 1 and 2 years of age received at least one prescription during 2002, this was
the case for only 36% of young people 11 years old or older.
As for socioeconomic factors, Henricson et al. (1998) show that the level of income
is positively correlated with the use of antibiotics. Attitudes towards antibiotics may
also be aﬀected by cultural/linguistic aspects. Lecomte and Paris (1994) suggest
that sociocultural factors may explain diﬀerences in consumption patterns between
European countries. Elsevier et al. (2006) show that southern European countries
consume higher doses of outpatient antibiotics per capita. Since Swiss regions are
characterised by German-, French- and Italian-speaking communities, we want to
investigate whether these linguistic communities’ attitudes towards antibiotics mirror
those of German, French and Italian speaking countries in Europe. Filippini et al.
6Swiss pediatricians cite the danger of potentially fatal complications of bacterial infections
in children (whose resistance is lower than adults’), such as rheumatic fever from streptococcus
infections. The incidence of rheumatic fever among children has declined a great deal historically,
but no one has been able to discern whether this is due to antibiotic use or just generally improved
hygienic conditions. Lacking data, doctors are inclined to prescribe antibiotics when children test
positive for bacterial infections.
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(2006) show that French- and Italian-speaking cantons consume more antibiotics
compared to German-speaking cantons. This claim can now be inspected using data
from small areas. Forty-four percent of our small areas are characterized by Latin
(French and Italian) culture. Around 12.5% of the areas have a border with a foreign
country. The density of foreigners or working commuters from other countries may
also aﬀect the per capita use of antibiotics.
The characteristics of the local supply of community health care can be captured
by the availability of practices and pharmacies in the area. In our dataset the number
of physicians per 100000 inhabitants ranges from 43 to (in one special case) 10730.
The coeﬃcient of variation is around 3 and suggests that there are large variations
across the areas. Besides physicians’ density we observe large diﬀerences in the den-
sity of pharmacies across the small areas. The number of pharmacies per 100000
inhabitants varies between 4.8 to 333. In the context of primary care, Grytten and
Sorensen (2003) find that physician-specific eﬀects in Norway explain between 47%
and 66% of diﬀerences in expenditure. Folland and Stano (1990) suggest that the
primary care physician to population ratio reflects the supply of medical services
and constitutes a potential explanation for small area variations in the use of health
care services. Similarly, we hypothesise that the density of physicians may aﬀect the
probability of antibiotic prescriptions under imperfect information on the impact of
bacterial resistance, ceteris paribus.
Diﬀerences in the incidence of infections among geographic areas are also likely
to impact the per capita use of antibiotics. Note, however, that remarkable seasonal
fluctuations suggest that the incidence of the most relevant community-acquired in-
fections, such as influenza and pneumonia, also vary widely during the year. Data on
bacterial infections are based on information on the incidence of common gastroin-
testinal and respiratory diseases. As indicators we use the incidence of campylobactor
and salmonella infections, the leading causes of gastrointestinal infections, and the
incidence of streptococcus pneumonie infections which represent the most common
airborne bacterial infections among the population. In most cases patients recover
without any medical treatment. However, patients, especially children and elderly
patients, may be prescribed antibiotics when symptoms are particularly severe. Data
on gastrointestinal infections are generally more reliable than those for airborne bac-
terial infections. However, the latter are also included in the model lest their omission
impact residual variations.7 Our information comes from yearly publications of the
Swiss Federal Statistical Oﬃce at the cantonal level.
Although individuals bear only a small fraction of the cost of antibiotics, diﬀer-
ences in health insurance copayments and deductibles may influence the price elas-
ticity of the demand. Moreover, competition and wholesalers’ marketing strategies
7Since residual variations are used in section 3.1 to calculate the welfare loss from attitudes
towards bacterial resistance, our model assumes that the variability in the use of antibiotics due
to the spread of diseases is accurately captured by the two indicators. Of course, we are aware
that residual variations may be influenced by the incidence of infectious diseases besides those
modeled in the paper. However, the inclusion of foodborne, waterborne and airborne infections may
substantially reduce this possibility.
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may vary across the areas, thus leading to significant price diﬀerences. Consequently,
the price of antibiotics may account for variance in consumption across small areas.
The price of a defined daily dose is calculated quarterly and varies between CHF 2.81
and CHF 4.80.
The information on prescription and consumption practices related to doctors’
and patients’ risk aversion in the use of antibiotics has been omitted in our model
and local rates of antimicrobial resistance cannot be observed. The interpretation of
unexplained variations from equation (1) will be addressed in detail in Section 3.1.
To investigate the responsiveness of local per capita antibiotic sales to changes
in the explanatory variables, we use a linear specification8 of the model defined by
equation (1). Coeﬃcients represent changes in the value of the dependent variable
corresponding to variations in the value of each explanatory variable, ceteris paribus.
Unexplained variations are assumed to be independently and identically normally
distributed.
From the econometric point of view, we should consider that our dataset is char-
acterised by a relatively small number of time periods (t = 3), a relatively large
number of cross-sectional units (N = 240) and zero within-variation for most of the
explanatory variables. The only two variables that change over time (three quarters)
are the outpatient per capita consumption and the price of a daily dose. Hence, the
typical model for panel data, e.g. the least squares dummy variable model and the
error components model, are not appropriate.9
An econometric problem that could arise when estimating the demand model (1)
is spatial correlation due to spatial dependency in antibiotics consumption. For this
reason, we use a spatial two-stage least-square (S-2SLS) estimation procedure.10
Since we use time lags for the price, the first quarter (January, February and
March) is excluded from the regressions. The estimation is performed using the
econometric software STATA.
8This simplifies the following analysis of the welfare loss due to heterogeneous attitudes toward
the risk of bacterial resistance, and implies that the marginal individual benefit from consumption
of a defined daily dose of antibiotics varies at constant rates. Although non-linear demands may be
more realistic, results from our linear regression show that the adjusted R-squared is quite high and
alternative specifications (log-log) add little.
9The reliability of these estimators depends on the extent of within-regional as well as between-
regional variations of the dependent and the independent variables. As Cameron and Trivedi (2005)
point out, the fixed-eﬀects approach has an important weakness in that the coeﬃcients of the
explanatory variables are “very imprecise” if the variable’s variation over time is dominated by
variation across regions (between variation).
10We estimate a spatial-lag model (using Spatial Two-Stage Least-Square estimation) which as-
sumes that the spatially weighted average of consumption in adjacent regions (DID−i) aﬀects the
consumption in each region in addition to the standard explanatory variables. Spatial lags of ex-
ogenous variables and cantonal dummies are used as a set of instruments to estimate the mean
antibiotic consumption in regions which are contiguous with region i. For more detailed explanation
see Anselin (2001) and Kelejian and Prucha (1998).
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3.1 Unexplained variations
We now focus on the analysis of unexplained variations in the use of antibiotics
in ambulatory care after controlling for the demand and supply-side determinants
considered above. The literature suggests that unexplained variations in medical
practice may be associated with unobserved heterogeneity in physicians’ practice
styles but omitted factors may also be related to patients’ preferences. As posited by
Stano (1993) patients’ preferences may interfere with the impact of practice style in
the residual variations.
In the case of antibiotics, unexplained variations are plausibly related to diﬀer-
ences in doctors’ and patients’ attitudes towards the risk of antibiotic treatment, i.e.
the impact of bacterial resistance. National average levels of bacterial resistance are
common knowledge but doctors and patients may be assumed to diﬀer in their level of
risk aversion. Doctors have two options: prescribe antibiotics at the first consultation
despite uncertainty about the nature of the infection, or delay antibiotic treatment
until the type of infection is determined. The former strategy may appease the pa-
tient but increases the risk of developing bacterial resistance. The latter strategy
reduces the risk of bacterial resistance but may increase recovery time, and hence the
opportunity cost for the patient.
P* 
V 1(D ID ) 
V 0(D ID ) 
V *(D ID ) 
D ID * D ID 1 D ID 0 
Increm ental value 
Price 
D ID  
Figure 2: The loss of consumer surplus due to variations in the use of antibiotics
(shaded areas). Heterogeneous attitudes towards bacterial resistance lead to shifts in
the “fully informed” demand cure (V ∗) to “uninformed” locations (V0 and V1).
We assess the welfare loss from unobserved heterogeneity in the use of outpatient
antibiotics building on a frame developed by Parente and Phelps (1990). The method
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relies on the determination of the loss of consumer surplus due to a shift in the
linear demand curve. Figure 3 illustrates the market for antibiotic treatment. We
presume that local variations arise from parallel shifts in the antibiotic demand curve
between observed “uninformed” locations (V0 and V1) and a “fully informed” demand
curve (V ∗) to which patients would move if they possessed all relevant information
about the value of antibiotics. The “fully informed” demand curve would be the
aggregate of all value curves for individuals and captures the social marginal benefit
of antibiotic utilisation. This means that the implications of bacterial resistance are
also taken into account. We assume that bacterial resistance does not vary locally and
the aggregate level of antibiotic resistance is common knowledge among prescribers.
This assumption is plausible given the low average levels of antibiotic consumption
in Switzerland. Marginal benefits of antibiotic treatment are decreasing at constant
rates. Many analyses of medical interventions rest upon this assumption. In the case
of antibiotics, increasing daily doses may reduce antibiotic eﬀectiveness because of
the selection of resistant bacteria.
The level of antibiotic use that maximises consumer’s well-being (DID∗) in each
small area is the point where the marginal value just equals the marginal cost of
antibiotic treatment (p∗). We calculate the “optimal” amount of antibiotics as the
average per capita rate of antibiotic use across all the small areas. Antibiotic use in
each area measures consumption by the representative individual. This is ensured by
the homogeneity of individuals’ characteristics within each area.
The marginal cost of a defined daily dose is constant and is given by the aver-
age antibiotic price across the areas.11 This requires that the market price represent
the full cost of antibiotic use and that patients do not incur additional incremental
costs. Patients generally pay drug costs until their deductible has been reached. The
cost of a consultation represents a fixed cost that presumably does not increase with
the number of individual doses. It also requires that the market for antibiotics be
competitive. Generally, new, branded new antibiotics are sold under patent protec-
tion. Their market price may include research and development costs of new drugs
since bacterial resistance undermines the eﬀectiveness of previous generations of an-
tibiotics. Note, however, that many types of antibiotics are traded in the generic
drug market and that regulators are increasingly adopting mechanisms of reference
pricing, which imply comparison with prices set in other countries.
Given this frame, we can quite naturally estimate the welfare loss from under- and
over-consumption due to cross-area diﬀerences in utilisation. The procedure uses the
residuals from equation (1) in order to account for systematic diﬀerences in con-
sumption across areas due to factors such as age, income, price and infections.12 Our
explanatory factors are unaﬀected by the demand for antibiotics in outpatient care,
11The price of a daily dose may fluctuate across small areas for at least two reasons. First,
antibiotic classes may be used in diﬀerent proportions across the areas. Second, discount strategies
may be applied by the wholesalers to the retailers.
12Of course, we are aware that the estimated welfare loss associated with variations may be
susceptible to error if some of our assumptions do not hold. For further discussion see the debate
between Dranove (1994) and Phelps (1995) on this issue.
11
and are thus truly exogenous. The incidence of mild respiratory and gastrointestinal
epidemic infections (for instance, influenza) is presumably independent of antibiotic
use in outpatient care. Physicians’ and pharmacies’ density are also independent of
antibiotic consumption in the community since licences are usually regulated by the
cantons. The slope of the demand curve is represented by the estimated coeﬃcient
of price from the linear regression of equation (1).
Since demands are linear, the total daily loss for 1000 inhabitants due to the misuse
of antibiotics (shaded areas in Figure 3) adds up all of the values of inappropriate
consumption over the N areas. Hence, the total loss is the sum of all the welfare loss
triangles:
W =
1
2
XN
i=1
∆DIDi∆Vi (2)
where ∆DIDi and ∆Vi represent deviations from the “optimal” level DID∗ and V ∗.
The value of residual variations in the use of antibiotics is then obtained by summing
the value of deviations from the estimated (eﬃcient) level of antibiotic use across the
areas.
To approximate ∆Vi we assume that V 0 is the slope of the demand curve and we
have ∆V = V 0 (DIDi −DID∗). Then we can rewrite equation (2) as
WDID =
1
2
V 0
XN
i=1
(DIDi −DID∗)2 =
N
2
V 0σ2
DID
, (3)
where σ2
DID
is the variance of the defined daily doses per capita across the areas.
The above definition of welfare loss matches data available in the aggregate after
some algebraic adjustments. We define ε as the percentage of change in DID for
a one percent change in V . Hence, ε = (dDID/DID) /(dV/V ) = V/(V 0DID).
Similarly, we convert the variance measure into an expression using the coeﬃcient of
variation (CV ). Finally, the “correct” use of antibiotics provides value just equal to
the marginal cost of a daily dose. We divide the variance by the square of the average
use to obtain CV 2 = σ2/DID∗2. Thus, we can write equation (3) as
WDID =
1
2ε
CV 2V ∗DID∗N . (4)
We can re-scale (4) to calculate the total welfare loss for one year for the whole Swiss
population. We multiply WDID by (365POP ), where POP is the Swiss population
divided by 1000. We then obtain
WDDDs =
1
2ε
CV 2V ∗DDDs, (5)
where DDDs is the total number of doses used for one year by the entire Swiss pop-
ulation. Consequently, V ∗DDDs represents the total Swiss spending on outpatient
antibiotic use.
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4 Empirical results
Four groups of determinants of small area variations in outpatient antibiotic use are
included in the model defined by equation (1): (i) the incidence of infections; (ii)
the demographic, socioeconomic, and cultural aspects of the population; (iii) the
supply of health care in the community; and (iv) antibiotic price. A preliminary
investigation shows that correlation coeﬃcients between the dependent variable and
the explanatory factors are all significant on the basis of a two-tailed test.
The estimation results obtained using the S-2SLS estimation procedure are re-
ported in Table 2. The estimated spatial autoregressive parameter associated with
the lag termDID−i is significant and negative. This indicates that the S-2SLS model
should be preferred to the Ordinary Least Squares (OLS) model.13
Perhaps the first point to note is that the adjusted R2 suggests that selected
variables explain approximately 87% of small area variations in the use of antibiotics
in the community. This figure is very close to the one estimated in Filippini et
al. (2006) with a log-log model specification and cantonal data (the adjusted R2 is
between 0.887 and 0.9).
The positive relationship betweenDID and income is significant at less than 0.1%
and suggests that richer areas spend more on outpatient antibiotics per capita than
lower income areas. The result is in accordance with findings by Nilson and Laurell
(2005), who analysed the impact of socioeconomic factors on antibiotic prescriptions
in a Swedish city. Similarly, Henricson et al. (1998) found that antibiotic consump-
tion is higher in higher income districts. However, our coeﬃcient is relatively low
and may indicate that antibiotics in outpatient care are not as strong normal goods
as Baye et al. (1997) suggest for anti-infectives (elasticity around 1.3). Indeed, our
calculated income elasticity is 0.37.14 In a previous analysis at the regional level we
found negative income elasticity around 0.5. Our finding seems to indicate that the
Swiss higher-income population is likely to substitute alternative treatment for an-
tibiotics than the comparable American population considered in Baye et al.’s study.
This may be related to the awareness of the perverse eﬀects of bacterial resistance.
This explanation fits with the relatively low per capita antibiotic consumption in
Switzerland compared to other countries. Note also that Baye et al.’s study is based
upon 1984-1990 data. The increasing concern over the eﬀects of bacterial resistance
throughout the 1990s may have reduced the income elasticity of outpatient antibiotic
13Our result suggests the evidence of positive consumption externalities across the areas. Higher
antibiotic consumption in one area is significantly associated with lower antibiotic consumption in
adjacent areas. A plausible explanation for this result is related to the double role of antibiotics.
Antibiotics are used to cure bacterial infections and to prevent the spread of infections and bacterial
resistance to other individuals. Consequently, the use of antibiotics in one area minimises the spread
of infections in neighbouring areas. This implies that a smaller amount of antibiotics is required to
obtain the same level of health benefits. Although patients’ imperfect information may suggest that
this eﬀect is not internalised by the individual, antibiotic prescribers such as general practitioners
are quite likely aware of this eﬀect.
14We calculate elasticities at mean values of antibiotic use and covariates using summary statistics
in table 1 and the regression coeﬃcients of our estimation.
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Equation Obs. Parms RMSE Adjusted R2 F -Stat p-value
DIDi 720 15 4.6 0.87 319.64 0.000
DID−i 720 46 1.84 0.92 176.06 0.000
Covariates Coeﬃcients Std. Err. p-value
Constant 13.73944 5.251623 0.009
Y 0.000187 0.000033 0.000
POP1 50.74812 16.57302 0.002
POP2 -49.57082 20.33704 0.015
POP4 -49.55307 13.94125 0.000
POP5 -44.15414 12.45914 0.000
DBOR -0.165596 0.587630 0.778
DLAT -3.068978 0.511633 0.000
INF 0.018375 0.010098 0.069
INF2 0.012642 0.006187 0.041
DPHY 0.000555 0.000210 0.008
DPHA 0.297510 0.006029 0.000
Pt−1 -2.086065 0.637740 0.001
DID−i -0.189367 0.038492 0.000
DT2 -2.424057 0.439328 0.000
DT3 -2.668702 0.427910 0.000
Table 2: Determinants of outpatient antibiotic use (2002 quarterly) across small areas
from spatial two-stage least square regression.
expenditure over time, thus leading to our lower elasticity value. Finally, our data
may not capture the eﬀect of retailing strategies associated with income because such
strategies are not aimed at the final consumer. We use total outpatient antibiotic
wholesales to pharmacies, drugstores and medical practices, whereas Baye et al. use
retailing prescription data collected through surveys of a sample of pharmacies.
Our analysis of the impact of demographic variables on outpatient antibiotic con-
sumption is plausible. The impact of the proportion of children between 0 and 14
years of age on the total population (POP1) reflects some health considerations. Since
children are largely exposed to infections in childcare facilities and school, imperfect
information on the type of infection may lead physicians and parents to provide them
with antibiotics in order to minimise the risk of complications and possibly contagion.
In terms of elasticity, a 1% increase in the proportion of children increases the use of
antibiotics per capita by 0.72%.
Also of interest is the negative coeﬃcient of the proportion of individuals over
74 years of age (POP5) compared to the baseline category. The calculated elasticity
is −0.29. A similar impact is observed for the proportion of individuals between 60
and 74 (POP4) with elasticity around −0.58. This suggests that elderly people may
be less exposed to the risk of infections in the community or that they are more
concerned with the implications of bacterial resistance. However, it could also imply
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that elderly people are more likely to obtain hospital referrals for such infections,
ceteris paribus, and hence to receive antibiotic treatment within the hospital. Our
result is in accordance with findings by Mousquès et al. (2003), who investigated a
panel of general practitioners prescribing antibiotics for rhynopharingeal infections.
We argue that the consumption of anti-infectives in the community diﬀers from
the use of other health care services, and consequently does not follow the same
trajectory over over an individual’s lifetime. Antibiotic treatment is likely delayed in
the young and the elderly until confirmation of bacterial infection in order to avoid
resistance implications. On the other hand, the antibiotic therapy can be conceived
as a time-saving choice and hence more likely to be adopted by individuals in the
work force. The literature on the determinants of health care expenditure generally
suggests that the increasing prevalence of chronic health problems associated with
aging may cause an increase in the utilisation of health care services. For instance,
Di Matteo and Di Matteo (1998) and Di Matteo and Grootendorst (2002) investigate
the determinants of the real per capital provincial government health expenditure in
Canada using a log-log functional form. They calculate a slightly positive elasticity of
the proportion of the population aged over 64. However, the result is not confirmed
by a more recent study (Di Matteo, 2005).
Another point of interest is that areas at the border between Switzerland and other
countries may share similar attitudes towards antibiotics for at least two reasons.
Firstly, the foreign workers may influence the perception of the need for antibiotic
treatment in the area. Secondly, physicians’ attitudes regarding the prescription of
antibiotics may be influenced by practice styles and the public perception of the
need for antibiotics in neighbouring countries. We test this hypothesis in the light of
diﬀerences observed in antibiotic consumption across Europe (Goossens et al., 2005).
Previous findings by Filippini et al. (2006) show positive and significant coeﬃcients
for these covariates. The percentage of foreigners in the total population increases
the cantonal per capita outpatient antibiotic expenditure.
Although the “Latin” dummy suggests that antibiotic expenditure is higher in
French- and Italian-speaking cantons compared to German-speaking cantons, these
results are not confirmed by the current findings. The coeﬃcient of DBOR is not
significant. Moreover, the coeﬃcient of DLAT is negative. Areas characterised by
French and Italian culture are associated with lower antibiotic use compared to areas
with German culture. Note, however, that the univariate correlation with the de-
pendent variable is positive. Dropping DLAT from the multivariate model does not
aﬀect the other results significantly. The reason for such an eﬀect is plausibly the
interaction with local supply factors, i.e. the density of pharmacies. Since French-
and Italian-speaking areas generally exhibit a higher density of pharmacies compared
to German-speaking areas, it is diﬃcult to pinpoint the eﬀect of diﬀerent cultural
attitudes on the use of antibiotics.
The coeﬃcients of the incidence of infections exhibit the expected positive sign.
Both common gastrointestinal infections and common respiratory infections have an
impact at less than 10% significance level. This result suggests that epidemiological
diﬀerences are relevant in explaining variations in the use of antibiotics in the com-
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munity. However, outpatient antibiotic expenditure does not seem to be very elastic
with respect to epidemiological factors. Our calculated elasticities vary between 0.07
for respiratory infections and 0.18 for gastrointestinal infections. Similarly, Filippini
et al. (2006) find positive and significant coeﬃcients and their elasticity is very low.
Note that the lack of quarterly data on the incidence of bacterial infections in our
dataset may dilute the seasonal impact of infections on antibiotic consumption. Some
seasonal eﬀects are captured by time dummies.
Local supply factors are positively associated with the per capita antibiotic use.
The level of significance is higher for the density of pharmacies than for the density
of physicians. There is a slight correlation between the two covariates. We find that
a 1% increase in the density of physicians raises antibiotic consumption by 0.03%,
whereas the elasticity of antibiotic consumption to the density of pharmacies is 0.89.
The density of physicians is often used to measure the extent of the supplier-
induced demand (SID) phenomenon in the empirical literature.15 This variable is
likely to be associated with higher per capita use of antibiotics, if physicians can
compensate for the increased pressure on their income due to the reduced number of
patients per doctor by increasing the amount of services provided to each individual
(Carlsen and Grytten, 2004). The literature generally suggests that in systems where
physicians are paid under a fee-for-service scheme, akin to the Swiss one, overcon-
sumption of drugs is more likely. Given that daily doses are standardised, our result
may suggest that variations in physicians’ practices might either take the form of
diﬀerences in the number of antibiotic treatments per person or of diﬀerences in daily
dosage schedules.
On the other hand, a recent study by Davis et al. (2000) analyses medical prac-
tice variations in New Zealand and does not find any evidence of SID. Similarly, Di
Matteo and Grootendorst (2002) estimate that the per capita number of prescribing
physicians is a negative, although not a significant, determinant of Canadian drug ex-
penditure. More closely related to antibiotic consumption, Garcia-Rey et al. (2004)
find a negative correlation between the number of physicians per capita and diﬀer-
ences in antibiotic use across Spanish provinces. Supplier-induced demand may be
unlikely in the Swiss context since physicians generally do not receive remuneration
for prescriptions. More plausibly, physician density may increase the use of drugs
by reducing patients’ access costs to physicians services. Indeed, the strong impact
of the density of pharmacies may indicate that patients are more likely to purchase
antibiotics if a pharmacy is located nearby their residence, ceteris paribus.
As expected, price has a negative and significant impact on antibiotic use in the
area. Swiss consumers bear only a small fraction of the total cost of drugs directly
because of compulsory health insurance. However, antibiotic sales my be aﬀected
by price changes because of standardised deductibles and copayments. On the other
hand, the demand for antibiotics may be more inelastic compared to other types of
drugs since antibiotics are generally purchased under doctor’s prescription. Our esti-
mate of price elasticity (−0.66) is slightly lower in absolute value than that of Baye et
15See McGuire (2002) for a review.
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al. (1997), who calculate both compensated (−0.785) and uncompensated (−0.916)
own-price eﬀects. Our findings support their argument that anti-infectives have the
most significant own-price elasticities among all major pharmaceutical classes. Focus-
ing on the demand for one antibiotic class, the cephalosporins, Ellison et al. (1997)
calculate own-price elasticities for diﬀerent brand/generic names irrespective of drug
expenditure using US wholesale data from 1985 to 1991. Their estimates range from
−0.38 to −4.34. Our results could also be compared to the ones found in Rudholm
(2003), who derives own-price elasticities for three Swedish pharmaceuticals submar-
kets for each year between 1989-1996. However, it is the prescription drug market for
beta-receptor blocking agents that may be most similar to our outpatient antibiotic
market, although not identical. Mean own-price elasticities calculated by Rudholm
are also negative and significant at 5% level, ranging between −0.12 to −3.43. A
shorter range (from −1.62 to −2.13) is covered by elasticities estimated by Rizzo
(1999) using wholesales data from the US antihypertensive drug market.
Finally, we find remarkable seasonal eﬀects on antibiotic consumption. The base-
line season is represented by the fourth quarter, i.e. the autumn dummy (October,
November, December). Per capita outpatient antibiotic use is expected to be lower
in the second and the third quarters of the year, as pointed out by Goossens et al.
(2005). Our estimated coeﬃcients for the second and the third quarters (DT2 and
DT3) are both negative and highly significant. This connotes lower per capita outpa-
tient antibiotic use during spring and summer periods, possibly because the risk of
bacterial infections is then lower.
4.1 Welfare loss assessment
Using equation (5) above, we can calculate the total welfare loss from antibiotic use for
the Swiss population for one year. As stated in Section 3.1 we use the residuals from
the estimation of the demand curve defined by equation (1). With this procedure we
control for diﬀerences in the socioeconomic characteristics of the areas, the incidence
of infections and access to physicians and pharmacies.
The adjusted coeﬃcient of determination derived in Section 4 denotes that het-
erogeneity in physicians’ and patients’ attitudes towards antibiotic use accounts for
13% (1 − R2) of total variations. The unexplained residual variance σ2
DID
is com-
puted as the raw variance times (1−R2), the proportion of variance left unexplained
by the regression. We use this computation to calculate the coeﬃcient of variation
CV . Similarly, we compute the elasticity ε at average “correct” levels of antibiotic
use (DID∗) and marginal cost (V ∗) using the estimated price coeﬃcient from our
regression to approximate the slope of the demand curve V 0. Finally, our dataset
includes detailed information on the antibiotic sales for each small area quarterly.
We use this information to calculate the total spending on antibiotics for the entire
Swiss population in 2002.
We summarise the estimated components of equation (5) and results from the
assessment of the welfare loss in Table 3.We calculate that the annual misuse of an-
tibiotics amounts to € 6777659, representing 12% of the total spending in outpatient
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antibiotics in 2002. Thus, we have identified the expected benefit (€ 6777659) of
reducing variations in antibiotic use due to heterogeneous attitudes toward bacterial
resistance. (Our argument is based on the premise that the average rate of antibiotic
consumption is optimal.)
σ2 DID∗ (1−R2)CV 2 1/ε Total spending Welfare Loss %
CHF € CHF €
170.60 11.71 0.159 1.51 88404476 56358839 10631436 6777659 12.03
Table 3: Assessment of the welfare loss from attitudes towards antibiotic use and
implications of bacterial resistance.
It is worth noting that the calculated welfare loss could be understated or over-
stated.16 First, our data are aggregated to the level of the area and cannot capture
within-area variation in the treatment of patients. This may cause us to understate
the overall welfare loss due to doctors’ attitudes towards the risk of bacterial infec-
tions. However, the small size of our areas and their internal homogeneity minimises
this risk. Second, society is assumed to produce antibiotics at a constant incremental
cost. Overall welfare loss may exceed our estimate if costs of production increase with
the scale of production. Indeed, this may be realistic if bacterial resistance reduces
the eﬀectiveness of antibiotic treatment and consequently increases the costs of pro-
ducing new, eﬀective antibiotics. Finally, if the current average rate of antibiotic use
is biased our measure of the welfare loss will also be biased. Clearly any additional
gains from reducing systematic bias in use will not be measured by our approach.
5 Conclusion
Understanding antibiotic treatment practices is necessary in order to reduce antibi-
otic misuse and the cost of bacterial resistance. The major contribution of this study
is the investigation of sources of small area variations in the use of antibiotics in the
community and the assessment of the impact of physicians’ and patients’ heteroge-
neous attitudes. We propose a model in which antibiotic use varies according to the
demographic and socioeconomic characteristics of the population, the incidence of
infections, the local supply of health care and the price of antibiotics. Estimations
are carried out on 2002 quarterly data of defined daily doses per 1000 inhabitants per
day (DID) available for 240 small areas in Switzerland. Results suggest that demo-
graphic and socioeconomic aspects only partially account for variations in outpatient
antibiotic use across small areas. Characteristics of the local supply, such as the
density of doctors, and consumption externalities across the areas are also relevant.
16The main reasons for possible bias are discussed in detail in Phelps and Parente (1990).
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Since antibiotics are associated with bacterial resistance, diﬀerences in physicians’
practice styles and patients’ attitudes are probably related to attitudes towards the
risks of bacterial resistance. Higher perceived levels of bacterial resistance induce
physicians to switch to newer and more expensive antibiotics in order to fight the
infection eﬀectively. The final eﬀect may be either an increase or a decrease in the
per capita defined daily doses.
Looking at unexplained variations across the small areas, we assess the impact
of heterogeneity in antibiotic treatment practices. Although the literature suggests
that there is a positive correlation between antibiotic use and resistance (Nilsson
and Laurell, 2005 and Garcia-Rey, 2004), the economic impact has not yet been
measured. Our assessment of the cost of variations in antibiotic treatment styles
may then provide a measure of the expected benefits of policy interventions aimed at
reducing the misuse of antibiotics.
The availability of information on the rate of bacterial resistance at the local
level would improve our estimation of the welfare loss. The lack of this information
prevents us from directly testing the eﬀect of bacterial resistance on the use of antibi-
otics. Data on bacterial resistance would also make it possible to distinguish between
physicians’ responsiveness to variations in bacterial resistance and other diﬀerences
in practice style.
Despite these limitations, the analysis provides a first assessment of the impact
of determinants of small area variations in the use of antibiotics in the community.
The literature on small area variations argues that diﬀerences in the utilisation of
health care resources are largely driven by physician practice style and supply vari-
ables rather than patient characteristics. Our findings add to this body of study
demonstrating the significant impact of local supply variables, but also by pointing
to patients’ attributes as an important factor in small area variations.
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